A trial of antibody targeted radiotherapy for relapsed low grade non Hodgkin lymphoma

Coronavirus and cancer

We know it’s a worrying time for people with cancer, we have information to help. If you have symptoms of cancer contact your doctor.

Read our information about coronavirus and cancer

Coronavirus and cancer

We know it’s a worrying time for people with cancer, we have information to help. If you have symptoms of cancer contact your doctor.

Read our information about coronavirus and cancer

Cancer type:

Blood cancers
Low grade lymphoma
Lymphoma
Non-Hodgkin lymphoma

Status:

Results

Phase:

Phase 3

This trial looked into the treatment of low grade non Hodgkin lymphoma (NHL) that had come back after it was first treated.

It used targeted radiotherapy that was given by injecting a monoclonal antibody that carried radiation. The antibody would find NHL cells throughout the body, so the radiation should be carried directly to those cells and the treatment should have fewer side effects.

The monoclonal antibody was called Bexxar (tositumomab).

The aim of the trial was to find out how well this treatment worked for relapsed low grade NHL.

Summary of results

The trial team found that Bexxar works well as treatment for low grade NHL that had come back after it was first treated.    

This trial recruited 89 people. Everyone had Bexxar.

Overall the number of people who responded to BEXXAR was 68 out of every 100 (68%). The average time it took for their NHL to come back was just under 2 years. The average length of time people lived after treatment was just over 5 years.

The trial team concluded that people with low grade NHL that had come back after treatment responded well to BEXXAR.

We have based this summary on information from the team who ran the trial.  As far as we are aware, the information they sent us has not been reviewed independently (peer reviewed Open a glossary item) or published in a medical journal yet. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Peter Johnson

Supported by

Coulter Pharmacutical Inc.

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle - 578

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Charlie took part in a trial to try new treatments

A picture of Charlie

“I think it’s really important that people keep signing up to these type of trials to push research forward.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think